Tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma
Approval of this first-in-class bi-specific T cell redirector, is based on results from an RCT which demonstrated superior overall survival (HR, intent-to-treat population, 0.51, 95% CI: 0.36, 0.71; p<0.0001) vs investigator’s choice (pembrolizumab, ipilimumab or dacarbazine).
Source:
Biospace Inc.